1112980-98-9

Basic information

• Product Name: N-(6-(5-(3-tert-butylphenylsulfonamido)-6-chloropyridin-3-yl)benzo[d]thiazol-2-yl)acetamide
• CAS NO: 1112980-98-9
• Molecular Weight: 515.057
• Mol File: 1112980-98-9.mol

Chemical Properties

• CAS DataBase Reference: N-(6-(5-(3-tert-butylphenylsulfonamido)-6-chloropyridin-3-yl)benzo[d]thiazol-2-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-(5-(3-tert-butylphenylsulfonamido)-6-chloropyridin-3-yl)benzo[d]thiazol-2-yl)acetamide(1112980-98-9)
• EPA Substance Registry System: N-(6-(5-(3-tert-butylphenylsulfonamido)-6-chloropyridin-3-yl)benzo[d]thiazol-2-yl)acetamide(1112980-98-9)

Safety Data

• Hazardous Substances Data: 1112980-98-9(Hazardous Substances Data)

Upstream product

• 588729-99-1 3-amino-5-bromo-2-chloropyridine 
• 2905-26-2 3-(tert-butyl)benzene-1-sulfonyl chloride 
• 15864-32-1 2-amino-6-bromobenzothiazole 
• 885069-14-7 N-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]acetamide 
• 1310049-08-1 C₁₅H₁₆BrClN₂O₂S 
• 16628-26-5 N-(6-bromo-1,3-benzothiazol-2-yl)acetamide 

Relevant articles and documents

Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors

Phosphoinositide 3-kinase α (PI3K-α) is a lipid kinase that plays a key regulatory role in several cellular processes. The mutation or amplification of this kinase in humans has been implicated in the growth of multiple tumor types. Consequently, PI3K- has become a target of intense research for drug discovery. Our studies began with the identification of benzothiazole compound 1 from a high throughput screen. Extensive SAR studies led to the discovery of sulfonamide 45 as an early lead, based on its in vitro cellular potency. Subsequent modifications of the central pyrimidine ring dramatically improved enzyme and cellular potency and led to the identification of chloropyridine 70. Further arylsulfonamide SAR studies optimized in vitro clearance and led to the identification of 82 as a potent dual inhibitor of PI3K and mTOR. This molecule exhibited potent enzyme and cell activity, low clearance, and high oral bioavailability. In addition, compound 82 demonstrated tumor growth inhibition in U-87 MG, A549, and HCT116 tumor xenograft models.

PI3 KINASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula I wherein each of A1, A2, A3, A4, X, R1 and R2 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of PI3 kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.